Estudo randomizado | AZD7442 (tixagevimabe–cilgavimabe) intramuscular para prevenir Covid-19.
25 Abr, 2022 | 12:29h
Comentário no Twitter
AZD7442 (tixagevimab/cilgavimab) found to have about 76% efficacy in preventing symptomatic Covid-19 infection. https://t.co/8tmvz3xI4I pic.twitter.com/fOegZjBRA6
— NEJM (@NEJM) April 20, 2022